以岭药业跌2.01%，成交额2.53亿元，主力资金净流出4762.95万元

Core Viewpoint - Yiling Pharmaceutical's stock has experienced fluctuations, with a recent decline of 2.01% and a year-to-date increase of 11.71% [1] Financial Performance - For the period from January to September 2025, Yiling Pharmaceutical reported revenue of 5.868 billion yuan, a year-on-year decrease of 7.82%, while net profit attributable to shareholders was 1 billion yuan, reflecting a year-on-year increase of 80.33% [2] Stock Market Activity - As of November 4, 2025, Yiling Pharmaceutical's stock price was 17.55 yuan per share, with a market capitalization of 29.321 billion yuan. The stock has seen a trading volume of 253 million yuan and a turnover rate of 1.04% [1] - The stock has appeared on the "Dragon and Tiger List" once this year, with a net purchase of 64.05 million yuan on January 6 [1] Shareholder Information - As of September 30, 2025, the number of shareholders was 152,700, a decrease of 10.22% from the previous period, with an average of 9,013 circulating shares per person, an increase of 11.38% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 8.1119 million shares, and a new shareholder, Changxin Jinli Trend Mixed A, holding 5.95 million shares [3] Dividend Distribution - Yiling Pharmaceutical has distributed a total of 4.455 billion yuan in dividends since its A-share listing, with 1.838 billion yuan distributed in the last three years [3] Industry Classification - Yiling Pharmaceutical is classified under the pharmaceutical and biological sector, specifically in traditional Chinese medicine [2]